Clinical Implication of Cyclophosphamide in Oncology, Hematology and Bone Marrow Transplantation (BMT)

Dastan Salim Hassan; Hemin Jumaa Majeed Hasary1

1

Publication Date: 2022/06/17

Abstract: Cyclophosphamide (Cytoxan; Cy) is an alkylating agent with immunosuppressive and cytotoxic action. The origin compound is out of action in vitro and utilizesits biologic activity over metabolites, principally phosphoramide mustard stemming from hepatic microsomal enzymes. The accurate process of cytotoxic and immunosuppressive activity of Cy at the cellular level is not ultimately presumed. Myelosuppression, alopecia, hemorrhagic cystitis, and gonadal disturbance are the main harmful consequence. Applicable information proposesthat Cy has carcinogenic probable in humans. Cy is greatly utilized as chemotherapy for cancer treatment, also as an immunosuppressive chemical, it is profitably used in specific nonmalignant diseases whether autoimmune phenomena are entrenched or suspicious in the pathogenesis of the disease. It is the preferred drug in Wegener's granulomatosis. Broad efforts are being made to generate Cy analogues with higher selective cytotoxic and immunosuppressive activity.

Keywords: Cyclophosphamide, cyclophosphamide and cancer, chemotherapy, toxic effect.

DOI: https://doi.org/10.5281/zenodo.6655187

PDF: https://ijirst.demo4.arinfotech.co/assets/upload/files/IJISRT22MAY1638_(1).pdf

REFERENCES

No References Available